about
Inhibition of NADPH-cytochrome P450 reductase and glyceryl trinitrate biotransformation by diphenyleneiodonium sulfateBlood pressures, heart rate and locomotor activity during salt loading and angiotensin II infusion in protease-activated receptor 2 (PAR2) knockout mice.Protection of protease-activated receptor 2 mediated vasodilatation against angiotensin II-induced vascular dysfunction in miceAttenuated vasodilator effectiveness of protease-activated receptor 2 agonist in heterozygous par2 knockout mice.Preserved arterial vasodilatation via endothelial protease-activated receptor-2 in obese type 2 diabetic miceProteinase-activated Receptor 2 (PAR2): a challenging new target for treatment of vascular diseases.Enantioselective inhibition of the biotransformation and pharmacological actions of isoidide dinitrate by diphenyleneiodonium sulphate.Protease-activated receptor 2 and bradykinin-mediated vasodilation in the cerebral arteries of stroke-prone rats.Proteinase-activated receptor-2 (PAR2): vascular effects of a PAR2-derived activating peptide via a receptor different than PAR2.Restricted ability of human mast cell tryptase to activate proteinase-activated receptor-2 in rat aorta.Hyperpolarization of murine small caliber mesenteric arteries by activation of endothelial proteinase-activated receptor 2.Developmental programming of lipid metabolism and aortic vascular function in C57BL/6 mice: a novel study suggesting an involvement of LDL-receptor.2-furoyl-LIGRLO-amide: a potent and selective proteinase-activated receptor 2 agonist.Effects of chronic in-vivo treatments with protease-activated receptor 2 agonist on endothelium function and blood pressures in mice.Perivascular Adipose Tissue-Enhanced Vasodilation in Metabolic Syndrome Rats by Apelin and -Acetyl⁻l-Cysteine-Sensitive Factor(s)Disturbance of vasodilation via protease-activated receptor 2 in SHRSP.Z-Lepr fa/IzmDmcr rats with metabolic syndrome.Persistence of PAR-2 vasodilation despite endothelial dysfunction in BPH/2 hypertensive miceEffects of poststroke losartan versus captopril treatment on myogenic and endothelial function in the cerebrovasculature of SHRsp
P50
Q28569170-6ED610F9-75F7-4023-951C-3F7C6A5456A1Q30849543-0037219F-15E6-4785-A489-AFCB6C11AD1EQ34034013-07D35E23-3C7E-44B5-8E41-87C1229E94CDQ34586508-B4FD185D-2D2D-439A-8317-BFFDE715D949Q35216480-C37EDC65-CD4F-4EE5-A507-99B9485E2D59Q35867203-764E25DC-ADA3-4027-AA11-BD0502E3641DQ42160164-40606AAB-9643-4656-97D5-058EF5CD6676Q43231950-DF458BDB-DFCE-479F-8BF8-81167AED9A37Q44220851-1142E708-DB8C-4A3E-8A55-7E45348148F0Q44227848-7C53F11A-E4A6-4B33-AA9A-35FF20DB8809Q45220380-DC2F560C-D5AF-48F1-81F8-58A5FC74D6C8Q46133222-B7CA572C-02B3-4C85-9396-1753FB2DB153Q51026666-E742777D-62B1-4B20-B7B0-D2F496B86785Q51032370-65785C93-057F-4987-AA86-A25BD35F0280Q60927699-AD5FD6A3-CA2C-4F1C-A9D3-88CBBA41A14EQ64969265-BF2350B0-471A-443B-9343-245EBF557D4FQ79822322-BFB89DDD-CEFF-4902-853D-A09540D415B2Q80019552-3768DD30-ED55-442A-B4ED-4DF7EBE64AF0
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
John J. McGuire
@ast
John J. McGuire
@en
John J. McGuire
@es
John J. McGuire
@nl
John J. McGuire
@sl
type
label
John J. McGuire
@ast
John J. McGuire
@en
John J. McGuire
@es
John J. McGuire
@nl
John J. McGuire
@sl
altLabel
John J. McGuire
@en
prefLabel
John J. McGuire
@ast
John J. McGuire
@en
John J. McGuire
@es
John J. McGuire
@nl
John J. McGuire
@sl
P106
P1153
35099078900
P21
P31
P3835
john-mcguire2
P496
0000-0003-0302-3884